UCHL1 and breast carcinoma: UCHL1 may promote doxorubicin (DOX) resistance in breast cancer (BC) by upregulating free fatty acid synthesis, as evidenced by reduced expression of FFA synthase and restored DOX sensitivity following UCHL1 inhibition (67).